Simplifying pre-medication for MS infusion treatments
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a shorter pre-medication routine before MS infusions to prevent allergic reactions. It compares a simple antihistamine (cetirizine) against the standard approach, which may reduce the number of pills you need before treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with multiple sclerosis (MS).
- You are taking or about to start one of these MS medications: ocrelizumab, ublituximab, or rituximab.
- You are not allergic to cetirizine (Zyrtec) or hydroxyzine (Vistaril).
- You do not have moderate or severe kidney problems.
- You have not had a prior allergic reaction that required extra pre-medication before your infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
This study tests whether a natural supplement called hesperidin (found in citrus fruits) can help people with MS. It aims to see if it is safe and well-tolerated.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.